mutations and complicated kar yotype. It follows a linear evolution from the CLL clone with the recurrent acquisition of CDKN2A Not all clients with CLL demand therapy. Regardless of all the latest advancements, the iwCLL nevertheless recommends watchful observation for clients with asymptomatic